Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122
Authors:
- Wilbur H ChenWCWilbur H Chen
- Eileen M BarryEBEileen M Barry
- Franklin R ToapantaFTFranklin R Toapanta
- Marcela F PasettiMPMarcela F Pasetti
- Marcelo B SzteinMSMarcelo B Sztein
- Jasnehta Permala-BoothJPJasnehta Permala-Booth
- Sharon M TennantSTSharon M Tennant
- Justin R OrtizJOJustin R Ortiz
- Megan McGilvrayMMMegan McGilvray
- Lynnee RoaneLRLynnee Roane
- Reva DatarRDReva Datar
- 18 April 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (1) , 9-19
Abstract
Background: There are no licensed vaccines to protect against Shigella or enterotoxigenic Escherichia coli (ETEC), yet they are among the most common causes of bacterial diarrhea. We engineered an attenuated Shigella flexneri 2a expressing colonization factor antigen 1 (CFA/I) and heat-labile enterotoxin B subunit (LTB) from ETEC and conducted a first-in-human randomized-controlled trial of ascending doses of the vaccine (CVD 1208S-122). Methods: Dose-escalating cohorts received a single oral dose of 108–1010 colony-forming units (CFU) of CVD 1208S-122 or placebo. A fourth cohort received 1 or 2 oral doses of 108 CFU CVD 1208S-122 or placebo. We measured the safety and clinical acceptability of the vaccine, genetic stability of fecally shed vaccine organisms, and immune responses elicited. Results: The 108 CFU doses were well tolerated (100%, 6/6). One recipient of 109 CFU (20%, 1/5) manifested diarrhea and 4 individuals who ingested 1010 CFU had either fever or diarrheal reactogenicity (67%, 4/6). Fecal shed vaccine organisms were genetically stable. Responses were observed to the lipopolysaccharide (LPS) and invasion plasmid antigen B (IpaB) of Shigella and CFA/I fimbriae and LTB of ETEC in serum, among antibody secreting cells, antibody in lymphocyte supernatant, and fecal samples. Serum antibodies exhibited Shigella bactericidal activity and inhibition of ETEC adherence in vitro. Conclusions: This study demonstrates safety with low-dose but unacceptable reactogenicity following highest-dose ingestion, genetic stability of all recovered fecal isolates, and immunogenicity of a prototype combined monovalent Shigella-ETEC vaccine. These results encourage expansion to a multivalent formulation to elicit broader protection against the most prevalent Shigella serotypes and ETEC CFA types that cause diarrheal disease. Clinical Trials Registration: NCT04634513.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (U01AI143493)
- Institute for Clinical and Translational Research, University of Maryland, Baltimore
- University of Maryland, Baltimore
- General Clinical Research Center, University of Maryland
- National Cancer Institute (P30CA134274)
- National Institute of Allergy and Infectious Diseases (U19AI181108)
- National Institute of Allergy and Infectious Diseases (U19AI109776)
- National Institute of Allergy and Infectious Diseases (U19AI142725)
- National Institute of Allergy and Infectious Diseases (R01AI132257)
- National Institute of Allergy and Infectious Diseases (P01AI125181)
This publication has 24 references indexed in Scilit:
- Gut-Homing Conventional Plasmablasts and CD27− Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in HumansFrontiers in Immunology, 2014
- Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine DevelopmentClinical Infectious Diseases, 2014
- Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic Escherichia coliClinical and Vaccine Immunology, 2013
- Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control studyThe Lancet, 2013
- Differential Host Immune Responses to Epidemic and Endemic Strains of Shigella dysenteriae Type 1Journal of Health, Population and Nutrition, 2011
- Safety and Immunogenicity of CVD 1208S, a Live, OralΔguaBA Δsen Δset Shigella flexneri2a Vaccine Grown on Animal-Free MediaHuman Vaccines, 2007
- Deletion in theShigellaEnterotoxin Genes Further AttenuatesShigella flexneri2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208The Journal of Infectious Diseases, 2004
- Shigella flexneri 2a Strain CVD 1207, with Specific Deletions in virG , sen , set , and guaBA , Is Highly Attenuated in HumansInfection and Immunity, 2000
- A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivityVaccine, 1995
- A STUDY OF THE RELATIONSHIP OF THE NORMAL BACTERICIDAL ACTIVITY OF HUMAN SERUM TO BACTERIAL INFECTION*Journal of Clinical Investigation, 1960